GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy Clinical Trial at Neuro2024
Press Releases
GemVax & KAEL  
October 29, 2024

GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy Clinical Trial at Neuro2024

- Topline supports moving to Phase 3 trial and shows potential to develop GV1001 as the world's first PSP treatment

logo salamanca press

Salamanca Press

Local & Social